Trial evaluates maternal vaccine to protect newborns from Group B Streptococcus. Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role in an international phase 1/2 clinical trial demonstrating the safety and immunogenicity of an investigational maternal vaccine against Group B Streptococcus (GBS)—a major cause of life-threatening infections in newborns worldwide.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role in an international phase 1/2 clinical trial demonstrating the safety and immunogenicity of an investigational maternal vaccine against Group B Streptococcus (GBS)—a major cause of life-threatening infections in newborns worldwide. The findings have been published in Nature Medicine.
- Ponto de atenção: trial.
- Ponto de atenção: evaluates.
- Ponto de atenção: maternal.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
